Sheng-Xiang Lin

List of Publications by Year
in descending order

133 papers	4,678 citations	117625 34 h-index	106344 65 g-index
135 all docs	135 docs citations	135 times ranked	4087 citing authors

#	Article	IF	Citations
1	CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer. Cancers, 2022, 14, 989.	3.7	8
2	Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic. Biomedicine and Pharmacotherapy, 2021, 137, 111232.	5.6	7
3	The multi-specific human 17 beta-hydroxysteroid dehydrogenase type 7: Non-competitive inhibitors can target different catalyses to facilitate breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology, 2021, 214, 105963.	2.5	1
4	An unprecedented endocrine target for ovarian cancer: inhibiting 17Î²-HSD7 supresses cancer cell proliferation and arrests G2/M cycle. American Journal of Cancer Research, 2021, 11, 5358-5373.	1.4	0
5	Steroid enzyme and receptor expression and regulations in breast tumor samples â€“ A statistical evaluation of public data. Journal of Steroid Biochemistry and Molecular Biology, 2020, 196, 105494.	2.5	4
6	Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer. Journal of Cellular Biochemistry, 2020, 121, 2756-2769.	2.6	11
7	Meta-Analysis of steroid-converting enzymes and related receptors in prostate cancer suggesting novel combined therapies. Journal of Steroid Biochemistry and Molecular Biology, 2020, 198, 105559.	2.5	2
8	Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks. Journal of Physical Chemistry Letters, 2020, 11, 4430-4435.	4.6	63
9	Using Omics to better understand steroid biosynthesis, metabolism, and functions. Journal of Steroid Biochemistry and Molecular Biology, 2020, 202, 105686.	2.5	0
10	Transcriptome of 17Î²-hydroxysteroid dehydrogenase type 2 plays both hormone-dependent and hormone-independent roles in MCF-7 breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2019, 195, 105471.	2.5	5
11	Mutual regulations and breast cancer cell control by steroidogenic enzymes: Dual sex-hormone receptor modulation upon 17Î²-HSD7 inhibition. Journal of Steroid Biochemistry and Molecular Biology, 2019, 193, 105411.	2.5	3
12	siRNA-based breast cancer therapy by suppressing 17β-hydroxysteroid dehydrogenase type 1 in an optimized xenograft cell and molecular biology model in vivo . Drug Design, Development and Therapy, 2019, Volume 13, 757-766.	4.3	7
13	Crystal structures of human 17Î²â€hydroxysteroid dehydrogenase type 1 complexed with estrone and <scp>NADP</scp>⁺ reveal the mechanism of substrate inhibition. FEBS Journal, 2019, 286, 2155-2166.	4.7	12
14	The dual sex hormone specificity for human reductive 17Î²-hydroxysteroid dehydrogenase type 7: Synergistic function in estrogen and androgen control. Journal of Steroid Biochemistry and Molecular Biology, 2019, 186, 61-65.	2.5	6
15	Cold-active extracellular lipase: Expression in Sf9 insect cells, purification, and catalysis. Biotechnology Reports (Amsterdam, Netherlands), 2019, 21, e00295.	4.4	8
16	CRIF1â€“CDK2 Interface Inhibitors: An Unprecedented Strategy for Modulation of Cell Radiosensitivity. Journal of the American Chemical Society, 2019, 141, 1420-1424.	13.7	11
17	Structure of Escherichia coli Arginyl-tRNA Synthetase in Complex with tRNAArg: Pivotal Role of the D-loop. Journal of Molecular Biology, 2018, 430, 1590-1606.	4.2	12
18	RNAâ€dependent RNA polymerase: Addressing Zika outbreak by a phylogenyâ€based drug target study. Chemical Biology and Drug Design, 2018, 91, 322-327.	3.2	4

#	Article	IF	Citations
19	Combined Biophysical Chemistry Reveals a New Covalent Inhibitor with a Low-Reactivity Alkyl Halide. Journal of Physical Chemistry Letters, 2018, 9, 5275-5280.	4.6	12
20	Steroid sulfatase inhibition success and limitation in breast cancer clinical assays: An underlying mechanism. Journal of Steroid Biochemistry and Molecular Biology, 2018, 183, 80-93.	2.5	16
21	17beta-hydroxysteroid dehydrogenase type 5 is negatively correlated to apoptosis inhibitor GRP78 and tumor-secreted protein PGK1, and modulates breast cancer cell viability and proliferation. Journal of Steroid Biochemistry and Molecular Biology, 2017, 171, 270-280.	2.5	21
22	Inhibition of 17beta-hydroxysteroid dehydrogenase type 7 modulates breast cancer protein profile and enhances apoptosis by down-regulating GRP78. Journal of Steroid Biochemistry and Molecular Biology, 2017, 172, 188-197.	2.5	12
23	Rapid and efficient oneâ€step purification of a serralysin family protease by using a pâ€aminobenzamidineâ€modified affinity medium. Journal of Separation Science, 2017, 40, 1960-1965.	2.5	1
24	Substrate inhibition of 17Î²-HSD1 in living cells and regulation of 17Î²-HSD7 by 17Î²-HSD1 knockdown. Journal of Steroid Biochemistry and Molecular Biology, 2017, 172, 36-45.	2.5	13
25	Estradiol-independent modulation of breast cancer transcript profile by 17beta-hydroxysteroid dehydrogenase type 1. Molecular and Cellular Endocrinology, 2017, 439, 175-186.	3.2	27
26	Structure-Based Design and Synthesis of a New Phenylboronic-Modified Affinity Medium for Metalloprotease Purification. Marine Drugs, 2017, 15, 5.	4.6	3
27	Structural Insight into NS5 of Zika Virus Leading to the Discovery of MTase Inhibitors. Journal of the American Chemical Society, 2016, 138, 16212-16215.	13.7	52
28	Genomic data on breast cancer transcript profile modulation by 17beta-hydroxysteroid dehydrogenase type 1 and 17-beta-estradiol. Data in Brief, 2016, 9, 1000-1012.	1.0	17
29	Current physico-biochemistry in steroid research and status of structural biology for steroid-converting enzymes. Journal of Steroid Biochemistry and Molecular Biology, 2016, 161, 1-4.	2.5	2
30	Human 3Î±-hydroxysteroid dehydrogenase typeÂ3: structural clues of 5Î±-DHT reverse binding and enzyme down-regulation decreasing MCF7 cell growth. Biochemical Journal, 2016, 473, 1037-1046.	3.7	15
31	Current knowledge of the multifunctional 17Î²-hydroxysteroid dehydrogenase type 1 (HSD17B1). Gene, 2016, 588, 54-61.	2.2	51
32	Affinity purification of metalloprotease from marine bacterium using immobilized metal affinity chromatography. Journal of Separation Science, 2016, 39, 2050-2056.	2.5	9
33	Impact of structural modifications at positions 13, 16 and 17 of 16Î²-(m-carbamoylbenzyl)-estradiol on 17Î²-hydroxysteroid dehydrogenase type 1 inhibition and estrogenic activity. Journal of Steroid Biochemistry and Molecular Biology, 2016, 161, 24-35.	2.5	12
34	Mimicking postmenopausal steroid metabolism in breast cancer cell culture: Differences in response to DHEA or other steroids as hormone sources. Journal of Steroid Biochemistry and Molecular Biology, 2016, 161, 92-100.	2.5	6
35	Synergistic control of sex hormones by 17Î²-HSD type 7: a novel target for estrogen-dependent breast cancer. Journal of Molecular Cell Biology, 2015, 7, 568-579.	3.3	25
36	In vitro interactions between mammary fibroblasts (Hs 578Bst) and cancer epithelial cells (MCF-7) modulate aromatase, steroid sulfatase and 17Î²-hydroxysteroid dehydrogenases. Molecular and Cellular Endocrinology, 2015, 412, 339-348.	3.2	11

#	Article	IF	Citations
37	Reductive 17beta-hydroxysteroid dehydrogenases which synthesize estradiol and inactivate dihydrotestosterone constitute major and concerted players in ER+ breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2015, 150, 24-34.	2.5	30
38	Interplay between Catalysts and Substrates for Activity of Class Ib Aminoacyl-tRNA Synthetases and Implications for Pharmacology. Current Topics in Medicinal Chemistry, 2015, 16, 616-633.	2.1	2
39	Human 3-alpha hydroxysteroid dehydrogenase type 3 (3Î±-HSD3): The V54L mutation restricting the steroid alternative binding and enhancing the 20Î±-HSD activity. Journal of Steroid Biochemistry and Molecular Biology, 2014, 141, 135-143.	2.5	16
40	Interaction of Androst-5-ene-3Î²,17Î²-diol and 5Î±-androstane-3Î²,17Î²-diol with estrogen and androgen receptors: A combined binding and cell study. Journal of Steroid Biochemistry and Molecular Biology, 2013, 137, 316-321.	2.5	22
41	Dendritic Cell Immunoreceptor Is a New Target for Anti-AIDS Drug Development: Identification of DCIR/HIV-1 Inhibitors. PLoS ONE, 2013, 8, e67873.	2.5	9
42	Crystal Structures of Human Muscle Fructose-1,6-Bisphosphatase: Novel Quaternary States, Enhanced AMP Affinity, and Allosteric Signal Transmission Pathway. PLoS ONE, 2013, 8, e71242.	2.5	11
43	A Challenge for Medicinal Chemistry by the 17β-hydroxysteroid Dehydrogenase Superfamily: An Integrated Biological Function and Inhibition Study. Current Topics in Medicinal Chemistry, 2013, 13, 1164-1171.	2.1	32
44	17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration. Breast Cancer Research, 2012, 14, R92.	5.0	46
45	The Contribution of 17beta-Hydroxysteroid Dehydrogenase Type 1 to the Estradiol-Estrone Ratio in Estrogen-Sensitive Breast Cancer Cells. PLoS ONE, 2012, 7, e29835.	2.5	24
46	Comparison of Functional Proteomic Analyses of Human Breast Cancer Cell Lines T47D and MCF7. PLoS ONE, 2012, 7, e31532.	2.5	52
47	Structure Analysis of a New Psychrophilic Marine Protease. PLoS ONE, 2011, 6, e26939.	2.5	15
48	Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet. Antimicrobial Agents and Chemotherapy, 2011, 55, 4019-4027.	3.2	28
49	Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity. Antiviral Therapy, 2010, 15, 579-586.	1.0	17
50	17Î²-Hydroxysteroid Dehydrogenase Type 1 Stimulates Breast Cancer by Dihydrotestosterone Inactivation in Addition to Estradiol Production. Molecular Endocrinology, 2010, 24, 832-845.	3.7	66
51	Crystallization of the Membrane-Associated Annexin B1: Roles of Additive Screen, Dynamic Light Scattering, and Bioactivity Assay. Crystal Growth and Design, 2010, 10, 2528-2532.	3.0	0
52	Molecular therapy of breast cancer: progress and future directions. Nature Reviews Endocrinology, 2010, 6, 485-493.	9.6	104
53	The Ternary Structure of the Double-headed Arrowhead Protease Inhibitor API-A Complexed with Two Trypsins Reveals a Novel Reactive Site Conformation. Journal of Biological Chemistry, 2009, 284, 26676-26684.	3.4	46
54	Crystal structure of native cinnamomin isoform III and its comparison with other ribosome inactivating proteins. Proteins: Structure, Function and Bioinformatics, 2009, 74, 250-255.	2.6	11

#	Article	IF	Citations
55	Reductive 17Î²-hydroxysteroid dehydrogenases in the sulfatase pathway: Critical in the cell proliferation of breast cancer. Molecular and Cellular Endocrinology, 2009, 301, 183-190.	3.2	40
56	Binary and ternary crystal structure analyses of a novel inhibitor with 17Î²-HSD typeÂ1: a lead compound for breast cancer therapy. Biochemical Journal, 2009, 424, 357-366.	3.7	72
57	Cinnamomin: separation, crystallization and preliminary X-ray diffraction study. Amino Acids, 2008, 34, 239-243.	2.7	2
58	Design and synthesis of bisubstrate inhibitors of type 1 17Î²-hydroxysteroid dehydrogenase: Overview and perspectives. European Journal of Medicinal Chemistry, 2008, 43, 2298-2306.	5.5	31
59	An Extensive Study of Protein Phase Diagram Modification: Increasing Macromolecular Crystallizability by Temperature Screening. Crystal Growth and Design, 2008, 8, 4277-4283.	3.0	18
60	Structure-based Inhibitor Design for an Enzyme That Binds Different Steroids. Journal of Biological Chemistry, 2007, 282, 8368-8379.	3.4	42
61	Structure Function Analysis of West Nile Virus RNA Dependent RNA Polymerase: Molecular Model and Implications for Drug Design. Medicinal Chemistry, 2007, 3, 455-459.	1.5	1
62	Purification, Refolding, Crystallization and Diffraction Analysis of the Native and Selenomethionine-Substituted Rat Epidymal-Specific Lipocalin. Crystal Growth and Design, 2007, 7, 2167-2170.	3.0	2
63	Good Crystals, Still a Challenge for Structural Biology. Crystal Growth and Design, 2007, 7, 2124-2125.	3.0	8
64	Crystallogenesis of Steroid-Converting Enzymes and Their Complexes: Enzymeâ€“Ligand Interaction Studies and Inhibitor Design Facilitated by Complex Structures. Crystal Growth and Design, 2007, 7, 2206-2212.	3.0	4
65	Progress in Macromolecular Crystallogenesis. Crystal Growth and Design, 2007, 7, 2123-2123.	3.0	0
66	Crystallization and preliminary X-ray diffraction analysis of E. coli arginyl-tRNA synthetase in complex form with a tRNAArg. Amino Acids, 2007, 32, 479-482.	2.7	2
67	Estrone and estradiol C-16 derivatives as inhibitors of type 1 17Î²-hydroxysteroid dehydrogenase. Molecular and Cellular Endocrinology, 2006, 248, 236-238.	3.2	25
68	Structural basis of the multispecificity demonstrated by 17Î²-hydroxysteroid dehydrogenase types 1 and 5. Molecular and Cellular Endocrinology, 2006, 248, 38-46.	3.2	45
69	Threeâ€dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. Proteins: Structure, Function and Bioinformatics, 2006, 64, 301-307.	2.6	20
70	Is dehydroepiandrosterone a hormone?. Journal of Endocrinology, 2005, 187, 169-196.	2.6	417
71	Mapping of Steroids Binding to 17Î²-Hydroxysteroid Dehydrogenase Type 1 Using Monte Carlo Energy Minimization Reveals Alternative Binding Modesâ€. Biochemistry, 2005, 44, 7218-7227.	2.5	7
72	Estradiolâ€'Adenosine Hybrid Compounds Designed to Inhibit Type 1 17Î²-Hydroxysteroid Dehydrogenase. Journal of Medicinal Chemistry, 2005, 48, 8134-8147.	6.4	48

#	Article	IF	Citations
73	Crystal Structures of the Multispecific 17Î²-Hydroxysteroid Dehydrogenase Type 5: Critical Androgen Regulation in Human Peripheral Tissues. Molecular Endocrinology, 2004, 18, 1798-1807.	3.7	72
74	Identifying Androsterone (ADT) as a Cognate Substrate for Human Dehydroepiandrosterone Sulfotransferase (DHEA-ST) Important for Steroid Homeostasis. Journal of Biological Chemistry, 2004, 279, 2689-2696.	3.4	53
75	Cofactor Hydrogen Bonding onto the Protein Main Chain Is Conserved in the Short Chain Dehydrogenase/Reductase Family and Contributes to Nicotinamide Orientation. Journal of Biological Chemistry, 2004, 279, 16778-16785.	3.4	69
76	The zinc-binding site of a class I aminoacyl-tRNA synthetase is a SWIM domain that modulates amino acid binding via the tRNA acceptor arm. FEBS Journal, 2004, 271, 724-733.	0.2	23
77	Human SARS-coronavirus RNA-dependent RNA polymerase: Activity determinants and nucleoside analogue inhibitors. Proteins: Structure, Function and Bioinformatics, 2004, 57, 12-14.	2.6	10
78	Crystal structure of chloramphenicol acetyltransferase B2 encoded by the multiresistance transposon Tn2424. Proteins: Structure, Function and Bioinformatics, 2004, 57, 858-861.	2.6	2
79	Monoclonal antibodies assisting refolding of firefly luciferase. Protein Science, 2004, 13, 1851-1858.	7.6	14
80	Protein crystal growth on board Shenzhou 3: a concerted effort improves crystal diffraction quality and facilitates structure determination. Biochemical and Biophysical Research Communications, 2004, 324, 1081-1086.	2.1	3
81	Endocrine and Intracrine Sources of Androgens in Women: Inhibition of Breast Cancer and Other Roles of Androgens and Their Precursor Dehydroepiandrosterone. Endocrine Reviews, 2003, 24, 152-182.	20.1	500
82	Synthesis of a First Estradiol-Adenosine Hybrid Compound. Synthetic Communications, 2003, 33, 3183-3192.	2.1	17
83	Pseudoâ€symmetry of C19â€steroids, alternative binding orientations and multispecificity in human estrogenic 17Î²â€hydroxysteroid dehydrogenase. FASEB Journal, 2003, 17, 274-276.	0.5	88
84	How estrogenâ€specific proteins discriminate estrogens from androgens: A common steroidâ€binding site architecture. FASEB Journal, 2003, 17, 1334-1336.	0.5	14
85	Purification, Reconstitution, and Steady-state Kinetics of the Trans-membrane 17Î²-Hydroxysteroid Dehydrogenase 2. Journal of Biological Chemistry, 2002, 277, 22123-22130.	3.4	33
86	Crystal structure of human dehydroepiandrosterone sulphotransferase in complex with substrate. Biochemical Journal, 2002, 364, 165-171.	3.7	87
87	A concerted, rational design of type 1 17Î²â€hydroxysteroid dehydrogenase inhibitors: estradiolâ€adenosine hybrids with high affinity. FASEB Journal, 2002, 16, 1-26.	0.5	74
88	Purification, crystallization and preliminary X-ray diffraction results of human 17Î²-hydroxysteroid dehydrogenase type 5. Acta Crystallographica Section D: Biological Crystallography, 2002, 58, 1048-1050.	2.5	3
89	Human dehydroepiandrosterone sulfotransferase: purification and characterization of a recombinant protein. Journal of Steroid Biochemistry and Molecular Biology, 2001, 77, 159-165.	2.5	21
90	Chemical synthesis of 16Î²-propylaminoacyl derivatives of estradiol and their inhibitory potency on type 1 17Î²-hydroxysteroid dehydrogenase and binding affinity on steroid receptors. Steroids, 2001, 66, 821-831.	1.8	32

#	Article	IF	Citations
91	Human oestrogenic 17Î²-hydroxysteroid dehydrogenase specificity: enzyme regulation through an NADPH-dependent substrate inhibition towards the highly specific oestrone reduction. Biochemical Journal, 2001, 356, 269-276.	3.7	44
92	Crystallization and preliminary X-ray diffraction analysis of the chloramphenicol acetyltransferase from Tn2424. Acta Crystallographica Section D: Biological Crystallography, 2001, 57, 281-283.	2.5	4
93	Crystallization and preliminary X-ray crystallographic analysis of the human type 3 3Î±-hydroxysteroid dehydrogenase at 1.8â€…Ã… resolution. Acta Crystallographica Section D: Biological Crystallography, 2001, 57, 589-591.	2.5	5
94	Crystallization and preliminary crystallographic data of fructose-1,6-bisphosphatase from human muscle. Acta Crystallographica Section D: Biological Crystallography, 2001, 57, 847-849.	2.5	8
95	Crystallization and preliminary crystallographic results of apo and complex forms of human dehydroepiandrosterone sulfotransferase. Acta Crystallographica Section D: Biological Crystallography, 2001, 57, 1630-1633.	2.5	7
96	Structure of the Human 3Î±-Hydroxysteroid Dehydrogenase Type 3 in Complex with Testosterone and NADP at 1.25-Ã… Resolution. Journal of Biological Chemistry, 2001, 276, 42091-42098.	3.4	53
97	Critical Residues for the Specificity of Cofactors and Substrates in Human Estrogenic 17Î²-Hydroxysteroid Dehydrogenase 1: Variants Designed from the Three-Dimensional Structure of the Enzyme. Molecular Endocrinology, 2001, 15, 2010-2020.	3.7	55
98	Human oestrogenic 17Î²-hydroxysteroid dehydrogenase specificity: enzyme regulation through an NADPH-dependent substrate inhibition towards the highly specific oestrone reduction. Biochemical Journal, 2001, 356, 269.	3.7	26
99	Critical Residues for the Specificity of Cofactors and Substrates in Human Estrogenic 17Â-Hydroxysteroid Dehydrogenase 1: Variants Designed from the Three-Dimensional Structure of the Enzyme. Molecular Endocrinology, 2001, 15, 2010-2020.	3.7	30
100	Monte Carlo-minimized energy profile of estradiol in the ligand-binding tunnel of 17?-hydroxysteroid dehydrogenase: Atomic mechanisms of steroid recognition. , 2000, 38, 414-427.		21
101	Dehydroepiandrosterone and Dihydrotestosterone Recognition by Human Estrogenic 17Î²-Hydroxysteroid Dehydrogenase. Journal of Biological Chemistry, 2000, 275, 1105-1111.	3.4	50
102	Magnet Used for Protein Crystallization: Novel Attempts to Improve the Crystal Quality. Biochemical and Biophysical Research Communications, 2000, 275, 274-278.	2.1	86
103	The Study of Crystallization of Estrogenic 17Î²-Hydroxysteroid Dehydrogenase with DHEA and DHT at Elevated Temperature. Biochemical and Biophysical Research Communications, 2000, 277, 100-106.	2.1	7
104	Membrane-Bound Human 3Î²-Hydroxysteroid Dehydrogenase: Overexpression with His-Tag Using a Baculovirus System and Single-Step Purification. Protein Expression and Purification, 2000, 18, 169-174.	1.3	12
105	Role of 17Î²-Hydroxysteroid Dehydrogenases in Sex Steroid Formation in Peripheral Intracrine Tissues. Trends in Endocrinology and Metabolism, 2000, 11, 421-427.	7.1	124
106	Crystallization and preliminary crystallographic analysis of the snake muscle fructose 1,6-bisphosphatase. Acta Crystallographica Section D: Biological Crystallography, 1999, 55, 1342-1344.	2.5	6
107	Electrophoresis of hydrophobic proteins. Analytica Chimica Acta, 1999, 383, 101-107.	5.4	9
108	Two non-reactive ternary complexes of estrogenic 17Î²-hydroxysteroid dehydrogenase: crystallization and preliminary structural analysis. Journal of Steroid Biochemistry and Molecular Biology, 1999, 68, 239-244.	2.5	4

#	Article	IF	Citations
109	3D-structure of human estrogenic 17Î²-HSD1: binding with various steroids. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 425-429.	2.5	24
110	Crystallization and preliminary crystal structure of the complex of 17Î²-hydroxysteroid dehydrogenase with a dual-site inhibitor. Journal of Steroid Biochemistry and Molecular Biology, 1999, 70, 229-235.	2.5	8
111	Human Estrogenic 17Î²-Hydroxysteroid Dehydrogenase: Predominance of Estrone Reduction and Its Induction by NADPH. Biochemical and Biophysical Research Communications, 1999, 259, 489-493.	2.1	47
112	Pterin and Folate Reduction by theLeishmania tarentolaeH Locus Short-Chain Dehydrogenase/Reductase PTR1. Archives of Biochemistry and Biophysics, 1997, 342, 197-202.	3.0	51
113	The key role of 17Î²-hydroxysteroid dehydrogenases in sex steroid biology. Steroids, 1997, 62, 148-158.	1.8	448
114	Crystallization and preliminary Xâ€ray diffraction analysis of arginylâ€tRNA synthetase from Escherichia coli. Protein Science, 1997, 6, 2636-2638.	7.6	4
115	A technique of protein addition for repeated enlargement of protein crystals in solution. Techniques in Protein Chemistry, 1996, , 361-371.	0.3	2
116	Fluorescence-Energy Transfer in Human Estradiol 17beta-Dehydrogenase-NADPH Complex and Studies on the Coenzyme Binding. FEBS Journal, 1996, 235, 180-186.	0.2	37
117	Chromatography of hydroxysteroid dehydrogenases. Biomedical Applications, 1996, 684, 99-105.	1.7	2
118	The crystallogenesis of a human estradiol dehydrogenase-substrate complex. Journal of Crystal Growth, 1996, 168, 275-279.	1.5	16
119	A microcrystal selection technique in protein crystallization. Journal of Crystal Growth, 1996, 168, 181-184.	1.5	5
120	Rapid purification of the over-expressed membrane 3 Î²-hydroxysteroid dehydrogenase in the presence of detergents. Journal of Crystal Growth, 1996, 168, 142-149.	1.5	5
121	Crystal structure of human estrogenic 17Î²-hydroxysteroid dehydrogenase complexed with 17Î²-estradiol. Nature Structural and Molecular Biology, 1996, 3, 665-668.	8.2	136
122	Crystallization of human estrogenic 17Î²-hydroxysteroid dehydrogenase under microgravity. Journal of Crystal Growth, 1995, 156, 108-111.	1.5	5
123	Molecular Mechanism of Inhibition of Steroid Dehydrogenases by Licorice-Derived Steroid Analogs in Modulation of Steroid Receptor Function. Annals of the New York Academy of Sciences, 1995, 761, 341-343.	3.8	9
124	Human 17Î²-hydroxysteroid dehydrogenase: optical properties of its complex with NADP+. Journal of Steroid Biochemistry and Molecular Biology, 1995, 52, 77-81.	2.5	1
125	Structure of human estrogenic 17Î²-hydroxysteroid dehydrogenase at 2.20 Ã¥ resolution. Structure, 1995, 3, 503-513.	3.3	260
126	Human 17Î²-hydroxysteroid dehydrogenase: overproduction using a baculovirus expression system and characterization. Journal of Steroid Biochemistry and Molecular Biology, 1994, 50, 275-282.	2.5	34

#	Article	IF	Citations
127	Preparation of the apoenzyme and holoenzyme forms of human 17Î²-hydroxysteroid dehydrogenase. Biomedical Applications, 1993, 614, 159-163.	1.7	4
128	Crystallization and Preliminary X-ray Diffraction Analysis of the Complex of Human Placental 17Î²-Hydroxysteroid Dehydrogenase with NADP+. Journal of Molecular Biology, 1993, 234, 242-244.	4.2	57
129	Higher specific activity of the Escherichia coli glutamylt-RNA synthetase purified to homogeneity by a six-hour procedure. Protein Expression and Purification, 1992, 3, 71-74.	1.3	19
130	Preparative fast purification procedure of various proteins for crystallization. Journal of Crystal Growth, 1992, 122, 242-245.	1.5	5
131	Rapid purification yielding highly active 17Î²-hydroxysteroid dehydrogenase: application of hydrophobic interaction and affinity fast protein liquid chromatography. Biomedical Applications, 1992, 582, 71-76.	1.7	19
132	Stoichiometry of slow binding of palmitoylâ€CoA to liver glucokinase*. International Journal of Peptide and Protein Research, 1989, 34, 333-339.	0.1	0
133	DHEA, The Precursor of Androgens and Estrogens in Peripheral Tissues in the Human: Intracrinology. , 0, , .		0